Overview Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris Status: Completed Trial end date: 2020-03-06 Target enrollment: Participant gender: Summary Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris Phase: Phase 1 Details Lead Sponsor: Taro Pharmaceuticals USATreatments: ClindamycinClindamycin palmitateClindamycin phosphate